Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS.
Trovafloxacin pharmacokinetics were evaluated in 12 subjects with AIDS. By using a randomized design, single 200-mg doses of oral trovafloxacin and intravenous alatrofloxacin were administered. The mean absolute bioavailability was 91%. The pharmacokinetics of trovafloxacin when administered orally as the active form or intravenously as the prodrug (alatrofloxacin) are not altered in subjects with AIDS compared to those in healthy adults.
Lacy
M K
MK
Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, Kansas 66160, USA.
Nicolau
D P
DP
Nightingale
C H
CH
Geffken
A
A
Teng
R
R
Vincent
J
J
Quintiliani
R
R
D000163:Acquired Immunodeficiency Syndrome / Q000378:metabolism*; D000284:Administration, Oral; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D018592:Cross-Over Studies; D024841:Fluoroquinolones; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D009287:Naphthyridines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011355:Prodrugs / Q000493:pharmacokinetics; D018401:Sample Size
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D011355:Prodrugs; C106856:alatrofloxacin; C080163:trovafloxacin